Clinical Trial Update: Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immunogenicity of HIV DNA-C CN54ENV and CN54gp140 vaccines in healthy volunteers; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• HIV CN54gp140 vaccine
• HIV DNA-C CN54ENV vaccine

Snippet

Sponsor: Imperial College London | Conditions: HIV | Phase 1 | Status: COMPLETED | Results posted: 2025-01-31